2024
Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.Peer-Reviewed Original ResearchSickle cell diseaseDelayed hemolytic transfusion reactionQuality-adjusted life expectancyAlloimmunized patientsPatient populationRed blood cell alloimmunizationCell diseaseCost-effective interventionMedical expenditure of patientsHealth system perspectiveExpenditure of patientsIncremental cost-effectiveness ratioHemolytic transfusion reactionsUnited StatesMarkov cohort simulationCost-effectiveAverage patient populationCost-effectiveness ratioBirth cohortAnalytical time horizonAntibody historyCohort simulationTransfusionTransfusion reactionsLife expectancy
2013
Is intensive monitoring during the first transfusion in pediatric patients necessary?
Berg A, Courtney R, Krishnamurti L, Triulzi D, Yazer M. Is intensive monitoring during the first transfusion in pediatric patients necessary? Hematology 2013, 19: 304-308. PMID: 24074624, DOI: 10.1179/1607845413y.0000000122.Peer-Reviewed Original ResearchConceptsIntensive care unitFirst transfusionPediatric patientsElectronic medical recordsTransfusion historyICU managementTertiary care pediatric hospitalPatient's transfusion historyPatients' electronic medical recordsList of patientsBlood bank recordsICU admissionRegular wardSubsequent transfusionsSignificant hypotensionCare unitPediatric hospitalAcute reactionsMedical recordsICU teamTransfusion reactionsBlood productsSevere reactionsTransfusionPatients